LMF
BCRX icon

LMR Master Fund’s BioCryst Pharmaceuticals BCRX Stock Holding History

LMR Master Fund’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-21,844
Closed -$159K – 349
2013
Q3 		$159K Sell
21,844
-88,835
-80% -$451K 0.03% 278
2013
Q2 		$171K Buy
+110,679
New +$191K 0.02% 382

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

LMR Master Fund's BCRX Position: Q4 2013 in Review

LMR Master Fund sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2013, closing a stake of 21,844 shares — an estimated $159K sold.

LMR Master Fund first reported a position in BCRX in Q2 2013 and held it in 2 quarters. The position peaked at $171K in Q2 2013. 75 funds tracked by Wall St. Rank hold BCRX as of Q4 2013.

  • LMR Master Fund reported no remaining BioCryst Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • LMR Master Fund sold 21,844 BioCryst Pharmaceuticals shares in Q4 2013, an estimated $159K.
  • LMR Master Fund first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • LMR Master Fund's BioCryst Pharmaceuticals position peaked at $171K in Q2 2013.
  • 75 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2013.

Based on LMR Master Fund's 13F filing for Q4 2013, filed 14 Feb 2014.